SYNCOM FORMU (I) LTD (SYNCOMF) financials
SYNCOM FORMU (I) LTD (SYNCOMF) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]
- Market Cap: ₹2,063Cr.
- Current Price: ₹22.0
- Stock P/E: 24.3
- ROE: 17.6%
- ROCE: 24.8%
- Book Value: ₹4.39
- Dividend Yield: 0.46%
- 52W High / Low: ₹27.5/10.2
In Jun 2026, SYNCOM FORMU (I) LTD (SYNCOMF) reported sales ₹125 Cr and net profit ₹25 Cr.
Annual TTM: sales ₹495 Cr, net profit ₹85 Cr.
Shareholding: Promoters 50.57% (Sep 2026), FIIs 2.23% (Sep 2026), Public 47.20% (Sep 2026), No. of Shareholders 4,18,465% (Sep 2026).
| Category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 101 | 127 | 148 | 117 | 121 | 115 | 134 | 125 |
| Expenses | 90 | 112 | 131 | 101 | 103 | 93 | 113 | 99 |
| Operating Profit | 12 | 15 | 17 | 16 | 19 | 21 | 21 | 26 |
| OPM % | 12% | 11% | 12% | 14% | 15% | 18% | 16% | 21% |
| Other Income | 4 | 4 | 7 | 6 | 5 | 5 | 14 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 15 | 17 | 23 | 20 | 22 | 25 | 33 | 32 |
| Tax % | 25% | 24% | 24% | 22% | 25% | 25% | 25% | 23% |
| Net Profit | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 |
| EPS in Rs | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.20 | 0.26 | 0.26 |
| Raw PDF | — | — | — | — | — | — | — | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 206 | 245 | 216 | 222 | 257 | 461 | 486 | 495 |
| Expenses | 189 | 207 | 196 | 202 | 229 | 407 | 409 | 407 |
| Operating Profit | 17 | 38 | 20 | 20 | 28 | 54 | 77 | 87 |
| OPM % | 8% | 16% | 9% | 9% | 11% | 12% | 16% | 18% |
| Other Income | 5 | 7 | 12 | 15 | 13 | 17 | 31 | 33 |
| Interest | 1 | 0 | 2 | 3 | 5 | 1 | 1 | 1 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 7 | 7 |
| Profit before tax | 17 | 41 | 26 | 27 | 32 | 65 | 101 | 112 |
| Tax % | 18% | 28% | 24% | 24% | 26% | 24% | 24% | — |
| Net Profit | 14 | 29 | 20 | 20 | 24 | 49 | 76 | 85 |
| EPS in Rs | 0.18 | 0.37 | 0.23 | 0.21 | 0.25 | 0.52 | 0.81 | 0.90 |
| Dividend Payout % | 0% | 0% | 13% | 0% | 0% | 0% | 12% | — |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 78 | 78 | 79 | 86 | 94 | 94 | 94 | 94 |
| Reserves | 55 | 68 | 109 | 136 | 162 | 192 | 246 | 318 |
| Borrowings | 9 | 2 | 62 | 58 | 83 | 72 | 4 | 1 |
| Other Liabilities | 32 | 33 | 42 | 28 | 38 | 33 | 66 | 116 |
| Total Liabilities | 173 | 181 | 292 | 308 | 377 | 392 | 410 | 529 |
| Fixed Assets | 89 | 93 | 91 | 94 | 91 | 120 | 125 | 184 |
| CWIP | 0 | 0 | 0 | 6 | 26 | 0 | 0 | 0 |
| Investments | 2 | 1 | 11 | 43 | 64 | 66 | 93 | 109 |
| Other Assets | 83 | 87 | 189 | 165 | 196 | 206 | 192 | 237 |
| Total Assets | 173 | 181 | 292 | 308 | 377 | 392 | 410 | 529 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 4 | 6 | -2 | 16 | 10 | -6 | 23 | 58 |
| Cash from Investing Activity | 2 | 2 | -75 | -27 | -45 | 84 | -18 | -51 |
| Cash from Financing Activity | -0 | -7 | 72 | 8 | 35 | -15 | -68 | -3 |
| Net Cash Flow | 7 | 1 | -5 | -2 | 1 | 63 | -63 | 4 |
| Free Cash Flow | 10 | 4 | -5 | 5 | -10 | -14 | 13 | 47 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 66% | 61% | 24% | 113% | 86% | 6% | 70% | 105% |
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% |
| FIIs | 0.13% | 0.11% | 0.41% | 0.10% | 0.26% | 0.21% | 0.35% | 2.23% |
| Public | 49.30% | 49.32% | 49.02% | 49.33% | 49.17% | 49.23% | 49.07% | 47.20% |
| No. of Shareholders | 4,89,520 | 4,84,529 | 4,71,066 | 4,57,364 | 4,42,280 | 4,31,690 | 4,22,114 | 4,18,465 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 81 | 77 | 112 | 114 | 124 | 132 | 85 | 81 |
| Inventory Days | 37 | 39 | 51 | 51 | 53 | 49 | 49 | 81 |
| Days Payable | 57 | 49 | 66 | 36 | 52 | 33 | 52 | 96 |
| Cash Conversion Cycle | 61 | 67 | 96 | 129 | 124 | 148 | 81 | 66 |
| Working Capital Days | 74 | 88 | 28 | 33 | -4 | 51 | 95 | 85 |
| ROCE % | 9% | 12% | 21% | 11% | 10% | 10% | 19% | 25% |
Syncom Formu (i) Ltd
₹2,063Cr.
₹22.0
₹27.5/10.2
24.3
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of SYNCOM FORMU (I) LTD (SYNCOMF)?
The reported market capitalisation for SYNCOM FORMU (I) LTD (SYNCOMF) is ₹2,063Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of SYNCOMF?
The current price shown for SYNCOM FORMU (I) LTD (SYNCOMF) on Fincrux is ₹22.0 with a 52-week high/low of ₹27.5/10.2.
What is the P/E ratio of SYNCOM FORMU (I) LTD (SYNCOMF)?
The stock P/E for SYNCOM FORMU (I) LTD (SYNCOMF) is 24.3 on Fincrux, with ROE at 17.6% and ROCE at 24.8%.
What were SYNCOMF latest quarterly results?
For Jun 2026, SYNCOM FORMU (I) LTD (SYNCOMF) reported sales ₹125 Cr and net profit ₹25 Cr (figures in ₹ crore unless noted).
What are SYNCOMF annual sales and net profit?
For TTM, SYNCOM FORMU (I) LTD (SYNCOMF) shows sales of ₹495 Cr and net profit of ₹85 Cr on the Fincrux profit & loss statement.
Who owns SYNCOM FORMU (I) LTD (SYNCOMF)?
Latest shareholding for SYNCOM FORMU (I) LTD (SYNCOMF) on Fincrux: Promoters 50.57% (Sep 2026), FIIs 2.23% (Sep 2026), Public 47.20% (Sep 2026), No. of Shareholders 4,18,465% (Sep 2026).
Where can I find SYNCOM FORMU (I) LTD (SYNCOMF) financials?
SYNCOM FORMU (I) LTD (SYNCOMF) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show SYNCOMF balance sheet and cash flow?
Yes. The SYNCOM FORMU (I) LTD (SYNCOMF) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.